当前位置:首页 > 文献互助 > 互助详情

New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A Vmax, app Approach复制

用户gJMFtDW4laqk 10小时前 58 10 已关闭

DOI:复制

文献链接: 10.1016/j.dmd.2026.100248复制

其他信息:

X Li, C Hu, G Wei, T Chen, J Tao, J Wu…
Drug Metabolism and …, 2026
Elsevier
Inter-individual variability in drug response stems largely from metabolic enzyme activity differences, with cytochrome P450 3A (CYP3A) being the predominant enzyme whose fluctuations critically impact exposure to narrow-therapeutic-index drugs (eg, tacrolimus) and anticancer agents. Current clinical probes like midazolam (suboptimal hepatic uptake, sedation) and the erythromycin breath test (poor selectivity) remain inadequate. This study proposes deoxyschizandrin (DS), derived from Schisandra chinensis, as a novel in vivo …

互助时间线

2026-02-07 22:08:58 [关闭求助]

楼主用户gJMFtDW4laqk关闭了求助

2026-02-07 19:41:43 [发起求助]

最新发布的求助